Relay Therapeutics
BiotechUnited States
1
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
3
Indications↗
Distinct diseases across all programs
6
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
1 drugs in development
Phase 31
Phase 21
Phase 11
By Therapeutic Area
top 1
Oncology
150%
R&D Momentum
35/100
Pipeline Velocity
11/100
Trial Completion Rate
100/100
Pipeline Concentration
50/100
Pipeline Freshness
83/100
Strategic Signals
- ↗Active in Oncology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 9, 2026
Recruiting
A Phase 3 Open-Label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment With a CDK4/6 Inhibitor
Jul 3, 2026
Recruiting
A First-in-human Study of RLY-8161 for Treatment of Advanced NRAS-Mutant Melanoma and Other Solid Tumors
Earlier
Jun 13, 2025TrialA Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
Mar 29, 2023TrialFirst-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
Dec 8, 2021TrialFirst-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Oncology
Oncology
Breast Cancer
RLY-2608Phase 1
Unknown / Other
PIK3CA Mutation
RLY-2608Phase 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)